Novo Nordisk’s Desert Hub for Wegovy Pill Signals Global Ambition, but Goldman Keeps Neutral Rating

Danish drugmaker ships daily weight-loss pill to Gulf, Africa, and Central Asia from June 2026, leveraging no cold-chain storage; stock remains cautious despite Goldman Sachs target hike.

The sprawling logistics infrastructure around Dubai is about to become the nerve centre of Novo Nordisk’s oral weight-loss franchise. From 3 June 2026, the Danish drugmaker has begun channelling shipments of the Wegovy tablet to as many as 70 countries spanning the Gulf, Africa, and Central Asia. The move marks the first international market entry for the pill version of its blockbuster drug outside the United States, where it launched in January.

Unlike the injectable formulation, the daily tablet requires no cold-chain storage. That gives it a logistical edge in regions with unreliable refrigeration infrastructure — a critical advantage given that roughly 28% of adults in the UAE already live with obesity, a figure projected to swell to 7.5 million people by 2035. The drug’s approval from the Emirates Drug Establishment covers both weight management and the reduction of cardiovascular risk, a dual indication that sets it apart from many competitors.

Clinical data underpins the rollout

The oral Wegovy pill delivered an average weight loss of 16.6% over 64 weeks in the OASIS-4 study — a figure that tops the 12.4% seen with Eli Lilly’s experimental oral candidate orforglipron (brand name Foundayo) over 72 weeks. Novo Nordisk also presented fresh data at the ongoing American Diabetes Association (ADA) conference on the fixed-dose combination CagriSema, drawing from the Phase 3 REIMAGINE trial. That study is part of a broader pipeline push designed to show the company can recover momentum in GLP-1 drug development, where rivals have been gaining ground.

Wall Street remains cautious despite a higher target

Goldman Sachs responded to the expansion by raising its price target on Novo Nordisk shares from 263 to 305 Danish kronen on 3 June. Yet the bank maintained a “Neutral” rating, signalling that valuation improvements alone do not warrant full-throttled optimism. The stock last traded at the equivalent of €36.50 in Germany, down 0.9% on the day, and has shed more than 41% over the past 12 months. The 52-week trough of €30.25 is only 20% below current levels. While the shares have crept back above the 50-day moving average, they remain well below the 200-day line — a technical pattern that hints at a fragile recovery.

By some financial models, the company trades at a 54% discount to intrinsic value, with a price-to-earnings ratio of 10.07 and a market capitalisation of roughly $190 billion. Gross margins stand at 81% and net margins at 33%, offering ample operational flexibility. But the stock’s muted reaction to the Dubai hub news underscores just how much the market is fixated on the competitive threat from Eli Lilly.

Eli Lilly looms large over the growth story

Novo Nordisk still commands a 59.6% volume share of the global obesity market by brand and a 45.8% value share of the GLP-1 diabetes segment. But in the critical US market, Eli Lilly has overtaken it: Novo Nordisk’s share of semaglutide prescriptions stood at just 37.4% in early June. That competitive pressure, combined with ongoing pricing headwinds in the United States, explains why the market does not automatically cheer every new product launch.

The company plans to introduce the Wegovy tablet in additional Tier-1 markets during the second half of 2026. Starting prices in the UAE are set at roughly 773 dirham — competitive but not aggressive, reflecting a strategy of gradual rollout rather than all-out discounting. The hope is that global insurers will increasingly cover anti-obesity medications, and the Dubai hub could eventually help address demand that has long outstripped supply.

ADA conference and institutional caution provide the counterpoint

The ADA meeting, running from 5 to 8 June, is the next major catalyst. Novo Nordisk plans to showcase further pipeline progress, including data that could bolster confidence in CagriSema and other candidates. The oral Wegovy tablet contributed 2.26 billion Danish kronen in first-quarter revenue, representing about 3% of group sales, so the contribution remains modest but growing.

Meanwhile, institutional investors are turning more selective. Peapack Gladstone Financial Corp reduced its Novo Nordisk position by 25.5% in the fourth quarter, exiting with 73,091 shares valued at $3.719 million. For now, the stock’s trajectory will depend on whether the pill’s international expansion can translate into tangible market share gains — and whether the ADA data can convince sceptics that Novo Nordisk still has the pipeline firepower to challenge Eli Lilly head-on.